HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Soapbox, YENSA, Vegamour Among Fastest-Growing Cosmetics Companies On Inc. 5000

Executive Summary

Inc. 5000 ranks the fastest-growing privately held companies in the US. With three-year growth of nearly 2,200%, Soapbox came in at No. 198 on the 2021 list, outpacing other beauty and personal-care companies that had enviable showings nevertheless in a year of unprecedented challenges.

You may also be interested in...



Crown To Acquire StriVectin, Appoint Its President Chief Commercial Officer

StriVectin president Cori Aleardi will join Crown’s executive leadership team, helping to merge the businesses and drive growth across Crown’s brand portfolio, which includes PanOxyl acne wash, Blue Lizard Australian Sunscreen, the SkinPen microneedling device, and prescription skin creams.

FDA’s Proposed Order For Sunscreens, A First Under OTC Reforms, Reprises 2019 Proposed Rule

As anticipated, the US FDA’s proposed order for sunscreens released on 24 September creates a bridge to the agency’s 2019 proposed rule before the CARES Act overhauled OTC drug review in March 2020.

US FDA’s Proposed Sunscreen Order Due With Inquiry Ongoing Re Environmental Impacts

Industry anticipates a proposed administrative order from the US FDA by 27 September on OTC sunscreen drug products, including GRASE status of active ingredients. Meanwhile, the agency’s probe continues into UV filter environmental impacts, and the National Academy of Sciences is gathering information to weigh those possible ills against human health consequences of reduced sunscreen use.

Topics

UsernamePublicRestriction

Register

RS151683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel